Compare
Quoin Pharmaceuticals Ltd. vs Nexentis Technologies Inc. vs Incannex Healthcare Inc. vs Evofem Biosciences, Inc.
| Latest fiscal year | Quoin Pharmaceuticals Ltd. QNRX | Nexentis Technologies Inc. NXTS | Incannex Healthcare Inc. IXHL | Evofem Biosciences, Inc. EVFM |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-06-30 | 2025-12-31 |
| Revenue | n/a | n/a | $86.0K | $20.18M |
| Revenue growth (YoY) | n/a | n/a | +616.7% | +4.2% |
| Gross margin | n/a | n/a | n/a | 77.1% (computed) |
| Operating margin | n/a | n/a | n/m | 16.7% |
| Net margin | n/a | n/a | n/m | 1.9% |
| Net income | -$15.80M | -$4.00M | -$46.88M | $391.0K |
| EPS (Diluted) | n/a | -$8.61 | -$1.35 | $0.00 |
| Operating cash flow | -$13.54M | -$3.81M | -$12.51M | -$1.99M |
| Free cash flow | n/a | -$3.82M | -$12.52M | -$2.00M |
| Cash & equivalents | $3.82M | $3.83M | $15.04M | $578.0K |
| Total assets | $20.39M | $20.41M | $20.45M | $20.27M |
| Total liabilities | $7.27M | $4.67M | $7.06M | $89.71M |
| Shareholders' equity | $13.12M | $16.01M | $13.39M | -$74.34M |
| Return on year-end equity | -120.5% | -25.0% | -350.2% | n/a |
| Shares outstanding | 52.44M | 2.77M | 194.38M | 126.69M |
Revenue, most recent five fiscal years
| Fiscal year | Quoin Pharmaceuticals Ltd. | Nexentis Technologies Inc. | Incannex Healthcare Inc. | Evofem Biosciences, Inc. |
|---|---|---|---|---|
| Latest | $0 Ended 2021-12-31 | $210.0K Ended 2024-12-31 | $86.0K Ended 2025-06-30 | $20.18M Ended 2025-12-31 |
| 1 year earlier | $0 Ended 2020-12-31 | $263.0K Ended 2023-12-31 | $12.0K Ended 2024-06-30 | $19.36M Ended 2024-12-31 |
| 2 years earlier | $0 Ended 2019-12-31 | $394.0K Ended 2022-12-31 | n/a | $18.22M Ended 2023-12-31 |
| 3 years earlier | n/a | $438.1K Ended 2021-12-31 | n/a | $16.84M Ended 2022-12-31 |
| 4 years earlier | n/a | $232.3K Ended 2020-12-31 | n/a | $8.24M Ended 2021-12-31 |